This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Over the past decade, macro trends in healthcare have pushed life sciences companies to pursue increasingly sophisticated keyaccountmanagement (KAM) strategies and capabilities to provide unique offerings and value. This leads to fewer health systems treating a larger percentage of total patients each year.
She has 20 years’ experience in business development and keyaccountmanagement in the clinical trials arena. About Velocity Clinical Research Velocity Clinical Research helps biopharmaceutical and CRO customers find the right patients for their studies.
The goal is to create a collaborative relationship with stakeholders based around the development of the value propositions that address the needs of policy makers, patients and payers. A survey conducted by Cegedim revealed that KeyAccountManagement (KAM) was the technique that procured the best results for market access strategies.
The goal is to create a collaborative relationship with stakeholders based around the development of the value propositions that address the needs of policy makers, patients and payers. A survey conducted by Cegedim revealed that KeyAccountManagement (KAM) was the technique that procured the best results for market access strategies.
In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). Asaf Evenhaim, CEO, Crossix, explains that “connecting HCPs and patients to essential and timely education has long been the aim of pharma marketers.
Everything from training field personnel to navigate new tools more efficiently from remote environments, to changing both the offering and its customer platform (HCPs and patients) to create the highest level of value and impact will need renewed strategic attention. Leading Teams in the “New Normal” Environment.
Let’s take the ecosystem definition as an example and extend it: ‘’A healthcare customer ecosystem is an interconnected set of entities and organizations each playing a role in providing healthcare to a geographic-specific patient population.’’. Providers, payers and suppliers, also a distribution supply chain and the patients themselves.
Let’s take the ecosystem definition as an example and extend it: ‘’A healthcare customer ecosystem is an interconnected set of entities and organizations each playing a role in providing healthcare to a geographic-specific patient population.’’. Providers, payers and suppliers, also a distribution supply chain and the patients themselves.
The Nationwide Pharma Marketing Excellence Awards 2022 are designed to recognize individuals who have contributed to developing innovative pharmaceutical products and services that may aid in providing patients with top-notch healthcare. 3) Sagar Patil, Senior Deputy General Manager at USV Ltd.,
I’m not going to be able to message you to change the way you manage a patient population. If I want to change the way you manage these patients, that’s a different skillset. Let’s have a dialogue about what we can do to change how you manage your patient population and how we can improve it.”
With patients and staff among those evacuating, resource problems quickly arose. Requirements on imports, packaging, storage and circulation of medical products and devices have been eased, while continuing to uphold product requirements for efficacy and patient safety. Lessons learned and the road ahead.
I’ve worked in the pharmaceutical industry full-time for 24 years across a variety of roles but mostly within Leadership and Market Access, and latterly heading up KeyAccountManagement at Boehringer-Ingelheim. My career started as an RGN, and I continue to work in the NHS in renal medicine. Focus on Service-Redesign.
In the context of a new medical innovation where there is a high unmet patient need, this means patients are not getting rapid access to medicines that can positively impact or even extend their lives. This requires them to interact more intensively to assess, engage, and maintain connections with HCPs and key decision-makers.
Medical sales offer a compelling opportunity for individuals seeking involvement in healthcare innovation, with lucrative financial rewards and a chance to directly impact patient care. Advancement opportunities are only limited by your individual capabilities.
This disruption has changed the way doctors and cancer patients expect to experience services and products, and there is no going back now. Takeda Connect provides oncologists with information about their KeyAccountManager and Medical Science Liaison, alongside direct access at the click of a button. About the author.
When war broke out in Ukraine in early 2022, many clinical trial patients had to flee the country or relocate, presenting considerable disruption to existing clinical trials and risking data collection on medical products. The situation has tested business continuity plans to their limits. Credit: Oximio.
Toxic extractables and leachables (E&L) can originate from low-purity packaging materials, entering the drugs and harming patients. Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceutical companies.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content